Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia

Hill, S. Kristian; Schuepbach, Daniel; Herbener, Ellen S.; Keshavan, Matcheri S.; Sweeney, John A.

doi:10.1016/s0920-9964(03)00213-5

Cited by 154 publications

(117 citation statements)

References 65 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Despite good reliability and moderate to large factor loadings, verbal list learning was only modestly sensitive to change following atypical antipsychotic treatment in both batteries. This was consistent with previous findings of stable verbal memory deficits over time (Hawkins & Wexler, 1999;Hill et al, 2004a;Hoff et al, 1999). Thus, aside from documenting expected deficits in the disorder, evaluation of verbal learning may have limited utility in detecting cognitive effects of atypical antipsychotics.…”

Section: Psychometrics and Efficiencysupporting

confidence: 93%

“…Composite scores for the BACS were calculated as the mean of Z scores, separately computed for each measure relative to the mean and standard deviation of the healthy comparison sample used in the BACS validation study (Keefe et al, 2004). Consistent with previous reports characterizing first episode samples relative to healthy comparison samples with other batteries (Bilder et al, 2000;Hill et al, 2004a), the BACS composite indicated moderate overall cognitive impairment for participants who completed baseline (Z 5 21.54 6 0.93) and 12-week (5 21.49 6 0.92) assessments.…”

Section: Neurocognitive Measuresmentioning

confidence: 98%

“…Moderate to marked deficits are typically seen across a wide range of cognitive abilities, are present during the first episode of psychosis, and endure after pharmacological treatment (Hill et al, 2004a;Hoff et al, 1999). Moreover, cognitive deficits have been linked with long-term functional disability (Green, 1996).…”

Section: Introductionmentioning

confidence: 99%

“…In general, modest cognitive benefits from antipsychotic medications are characterized by reduction of generalized cognitive deficits across a wide range of abilities, rather than particular effects on a specific neuropsychological domain (Buchanan et al, 1994;Cassens et al, 1990;Hill et al, 2004a;Rollnik et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

Hill

Sweeney

Hamer

et al. 2008

J. Inter. Neuropsych. Soc.

View full text Add to dashboard Cite

Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n 5 367) and 12-week (n 5 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes. (JINS, 2008, 14, 209-221.)

show abstract

Section: Psychometrics and Efficiencysupporting

confidence: 93%

Section: Neurocognitive Measuresmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

Hill

Sweeney

Hamer

et al. 2008

J. Inter. Neuropsych. Soc.

View full text Add to dashboard Cite

show abstract

“…The prevention of relapses remain a major public health challenge and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as on direct and indirect health care costs. There is strong evidence that frequent relapses can increase the likelihood of poorer long-term outcome (Wiersma et al, 1998;Harrison et al, 2001;Hill et al, 2004). Recently volumetric magnetic resonance imaging studies confirmed that grey matter density loss occurs across the course of the illness in schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Jaeger

Rössler

2010

Psychiatry Research

127

135

View full text Add to dashboard Cite

In many countries fewer than 20% of individuals with schizophrenia receive depot antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's objections to depot treatment. This is the first study that directly compares the attitudes to depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire about their attitudes to depot antipsychotics was completed by 255 participants (83 patients diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, not directly related to the patients). Patients were more negative towards depot injections than psychiatrists and relatives. They particularly fear to be constricted in their autonomy when treated with depot antipsychotics and that injections might be painful. About 67% of all patients in our sample did not receive information about depot antipsychotics by their psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic episode. Psychiatrists use depot antipsychotics in a conservative way although they attribute positive traits to the method. Patients' negative attitudes might relate to the low level of information. To enhance the use of depot antipsychotics, information practices of psychiatrists should be improved. Patients should be informed about different applications forms already during early stages of the illness.

show abstract

Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia

Reilly

Harris

Keshavan

et al. 2006

Arch Gen Psychiatry

133

View full text Add to dashboard Cite

Deficits in the maintenance of spatial information in working memory are present early in the course of illness. Risperidone treatment exacerbated these deficits, perhaps by impairing the encoding of information into working memory. Studies with nonhuman primates performing oculomotor delayed response tasks suggest that the apparent adverse effect of risperidone might result from treatment-related changes in modulatory functions of prefrontal D1 receptor systems.

show abstract

Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia

Cited by 154 publications

References 65 publications

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia

Contact Info

Product

Resources

About